Page last updated: 2024-12-06
1-benzyl-4-piperidone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
1-Benzyl-4-piperidone is a key intermediate in the synthesis of various pharmaceuticals, particularly those targeting the central nervous system. Its structural similarity to natural neurotransmitters like dopamine makes it a valuable tool for studying receptor interactions and pharmacological effects. Research into 1-benzyl-4-piperidone focuses on its potential as a precursor to medications for treating conditions like Parkinson's disease and depression. Its synthesis often involves the reaction of 4-piperidone with benzyl bromide, leading to the formation of the desired compound. Further modifications to the molecule can lead to the development of new drugs with improved efficacy and reduced side effects.'
1-benzyl-4-piperidone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 19220 |
| CHEMBL ID | 491630 |
| SCHEMBL ID | 4726 |
| MeSH ID | M0510410 |
Synonyms (80)
| Synonym |
|---|
| EU-0099975 |
| AC-6376 |
| smr001559985 |
| NCIOPEN2_000865 |
| 1-benzylpiperidone |
| n-benzylpiperidin-4-one |
| n-benzylpiperidinone |
| nsc-77933 |
| n-benzyl-4-piperidinone |
| 1-benzyl-4-piperidone |
| 1-benzyl-4-piperidinone |
| 4-piperidone, 1-benzyl- |
| 1-benzyl-4-oxopiperidine |
| mls002694053 , |
| nsc77933 |
| n-benzyl-4-piperidone |
| 4-piperidone,1-benzyl |
| 1-benzylpiperidin-4-one |
| inchi=1/c12h15no/c14-12-6-8-13(9-7-12)10-11-4-2-1-3-5-11/h1-5h,6-10h |
| 4-piperidinone, 1-(phenylmethyl)- |
| 3612-20-2 |
| 1-benzyl-4-piperidone, 99% |
| B1027 , |
| HMS1648P07 |
| FT-0663028 |
| CHEMBL491630 |
| AKOS000119701 |
| NCGC00246875-01 |
| 399249ph5b , |
| einecs 222-782-4 |
| unii-399249ph5b |
| nsc 77933 |
| FT-0688557 |
| STL141066 |
| BP-10640 |
| FS-1714 |
| SCHEMBL4726 |
| benzyl-piperidin-4-one |
| 4-oxo-1-benzylpiperidine |
| n-benzyl-4-oxopiperidine |
| 1-(phenylmethyl)-4-piperidone |
| 1-(phenyl-methyl)-4-piperidinone |
| 1-benzyl4-piperidone |
| 1-benzyl-4-oxo-piperidine |
| 1-benzylpiperidine-4-one |
| 1 -benzyl-4-piperidone |
| 4-n-benzylpiperidone |
| 1-benzyl piperidin-4-one |
| 1-benzyl-4 -piperidone |
| n-benzylpiperdine-4-one |
| n-benzyl4-piperidone |
| 1-benzyl -4-piperidone |
| benzyl-4-piperidone |
| 1-benzylpiperid4-one |
| n-benzyl 4-piperidone |
| 1-benzylpiperid-4-one |
| 1-benzyi-4-piperidone |
| 1-benzyl-piperidin-4-one |
| 1-benzyl-piperid-4-one |
| 1-phenylmethyl-4-piperidone |
| 1-benzyl-4-piperdinone |
| n-benzylpiperidine-4-one |
| 1-phenylmethyl-4-piperidinone |
| 1-(phenylmethyl)-4-piperidinone |
| AM85336 |
| Q-200108 |
| mfcd00006192 |
| CS-W007822 |
| F0850-6847 |
| DTXSID30189695 |
| sr-01000597226 |
| SR-01000597226-1 |
| 1-benzyl-4-piperidone, technical, >=98.0% (gc) |
| Z54749061 |
| SY001468 |
| BCP22272 |
| EN300-16225 |
| Q27256879 |
| SB42971 |
| HY-W007822 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (14)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID387035 | Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Synthesis and potent antileukemic activities of 10-benzyl-9(10H)-acridinones. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 29.26
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.26) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||